Impact of Liraglutide 3.0 on Body Fat Distribution

NCT03038620 · Completed

Last updated 2026-05-28

This clinical trial tests whether the medication liraglutide at a 3.0 mg dose affects body fat distribution in adults with obesity.

Status Completed The study has finished.

Phase Phase 4 Monitors a drug already on the market.

Type Interventional (clinical trial)

Design Randomized, quadruple-blind prevention study

Participants 235 people

Who can join Ages 35+ · all sexes Healthy volunteers accepted.

Timeline Started 2017-01 · est. completion 2020-10

Where 1 site · United States

What this study is testing ClinicalTrials.gov NCT03038620 ↗

Description as written by the study sponsor.

This study is a clinical study to investigate the efficacy of liraglutide compared to placebo in reducing visceral adiposity measured by MRI in overweight or obese subjects at high risk for cardiovascular disease after 40 weeks on-treatment.

Treatments tested

Liraglutide also known as Saxenda Drug

Liraglutide is administered once daily by subcutaneous injections with the pen-injector, either in the abdomen, thigh or upper arm. Injections can be done at any time of day irrespective of meals. Subjects will be instructed to escalate the liraglutide dose to 3.0 mg/day over a 4 week period following an initial dose of 0.6 mg/day and weekly dose escalation steps of 0.6 mg/day.
Placebo also known as Saline injection Drug

Placebo is administered once daily by subcutaneous injections with the pen-injector, either in the abdomen, thigh or upper arm. Injections can be done at any time of day irrespective of meals. Subjects will be instructed to escalate the placebo dose to 3.0 mg/day over a 4 week period following an initial dose of 0.6 mg/day and weekly dose escalation steps of 0.6 mg/day.

Main thing measured	Relative Percent Reduction in Visceral Adipose Tissue Mass Measured by MRI
Sponsor	University of Texas Southwestern Medical Center
Conditions studied	Obesity, Visceral, Cardiovascular Diseases, Fat Disorder
GLP-1 drugs	liraglutide

Full protocol, eligibility, and contacts on ClinicalTrials.gov NCT03038620 ↗